Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

ClinicalTrials.gov ID: NCT03185481

Public ClinicalTrials.gov record NCT03185481. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE

Study identification

NCT ID
NCT03185481
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
5 participants

Conditions and interventions

Interventions

  • 1 mg QD to 15 mg QD PF-06649751 Drug
  • 3 mg QD to 15 mg QD PF-06649751 Drug
  • 7 mg QD to 15 mg QD PF-06649751 Drug
  • 15 mg QD PF-06649751 Drug
  • 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) Drug
  • 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) Drug
  • 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) Drug
  • 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD Drug

Drug

Eligibility (public fields only)

Age range
40 Years to 87 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 5, 2017
Primary completion
Oct 23, 2017
Completion
Oct 24, 2017
Last update posted
Apr 11, 2019

2017

United States locations

U.S. sites
9
U.S. states
8
U.S. cities
8
Facility City State ZIP Site status
Hoag Memorial Hospital Presbyterian Newport Beach California 92663
Associated Neurologists of Southern CT, PC Fairfield Connecticut 06824
Parkinson's Disease and Movement Disorders Center of Boca Raton Boca Raton Florida 33486
Atlanta Center for Medical Research Atlanta Georgia 30331
Pharmaceutical Research Associates, Inc. Marlton New Jersey 08053
University of Toledo, Gardner-McMaster Parkinson Center Toledo Ohio 43614
University of Toledo, Investigational Drug Services Toledo Ohio 43614
The Movement Disorder Clinic of Oklahoma Tulsa Oklahoma 74136
Booth Gardner Parkinson's Care Center Kirkland Washington 98034

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03185481, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 11, 2019 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03185481 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →